Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full NewsNon-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk
Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy
1.
Could CT scans be fueling a future rise in cancer cases, as a new study suggests?
2.
recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.
3.
Clinical trial is testing whether heavy lifting could combat cancer side effects
4.
By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review
2.
Exploring the Potential of Xospata: A New Frontier in Cancer Treatment
3.
Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics
4.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
5.
Breast Cancer Recovery: Fashion, Function, and Healing Beyond Scars
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XIII
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
3.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge